Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.

TitleEnhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.
Publication TypeJournal Article
Year of Publication2000
AuthorsPapasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ
JournalJ Infect Dis
Volume182
Issue3
Pagination766-75
Date Published2000 Sep
ISSN0022-1899
KeywordsAdult, Anti-HIV Agents, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Drug Administration Schedule, Female, HIV Infections, HIV-1, Humans, Immunity, Cellular, Interferon-gamma, Longitudinal Studies, Male, Middle Aged, Viral Load
Abstract

Immunologic and virologic outcomes of treatment interruption were compared for 5 chronically human immunodeficiency virus (HIV)-infected persons who have maintained antiretroviral therapy-mediated virus suppression, as compared with 5 untreated controls. After a median interruption of 55 days of therapy accompanied by rebound of virus, reinitiated therapy in 4 of 5 subjects resulted in suppression of 98.86% of plasma virus load by 21-33 days and no significant decrease in CD4 T cell percentage from baseline. Increased T helper responses against HIV-1 p24 antigen (P=. 014) and interferon-gamma-secreting CD8 T cell responses against HIV-1 Env (P=.004) were present during interruption of therapy and after reinitiation of treatment. The remaining subject whose treatment was interrupted did not resume treatment and continued to have a low virus load (<1080 HIV-1 RNA copies/mL) and persistent antiviral cell-mediated responses. In summary, cellular immunity against autologous HIV-1 has the potential to be acutely augmented in association with temporary treatment interruption in chronically infected persons.

DOI10.1086/315748
Alternate JournalJ Infect Dis
PubMed ID10950770
Grant ListAI44595 / AI / NIAID NIH HHS / United States
F31GM20068 / GM / NIGMS NIH HHS / United States
GM0773 / GM / NIGMS NIH HHS / United States
Related Faculty: 
Jonas Heymann, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700